Astra Zeneca Tops Indian Pharma in New Introductions 2024

Analysis of Indian Pharmaceutical Market (IPM) – 2024

This data provides insights into the top new introductions (NI) in the Indian Pharmaceutical Market (IPM) for the last 12 months (Dec 2023 - Dec 2024).

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Astra Zeneca Tops Indian Pharma in New Introductions 2024

Free Membership Required

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Topics

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

MedicinMan Pharma Pulse: August 2026

Related Articles

Biocon Bats for Affordable Insulin and Ozempic

Vivek V. Kamath Appointed CEO at PlasmaGen BioSciences

Is Your Field Force Optimised to Make the Most of Market Growth in Metros?

Astra Zeneca Tops Indian Pharma in New Introductions 2024

IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day

Company

Headlines

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

Newsletter